-
1
-
-
29244457275
-
Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis
-
Ardizzone S., Maconi G., Russo A., Imbesi V., Colombo E., and Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 55 (2006) 47-53
-
(2006)
Gut
, vol.55
, pp. 47-53
-
-
Ardizzone, S.1
Maconi, G.2
Russo, A.3
Imbesi, V.4
Colombo, E.5
Bianchi Porro, G.6
-
2
-
-
1542619846
-
Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis
-
Arts J., D'Haens G., Zeegers M., Van Assche G., Hiele M.D., Hoore D., Penninckx F., Vermeire S., and Rutgeerts P. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm. Bowel Dis. 10 (2004) 73-78
-
(2004)
Inflamm. Bowel Dis.
, vol.10
, pp. 73-78
-
-
Arts, J.1
D'Haens, G.2
Zeegers, M.3
Van Assche, G.4
Hiele, M.D.5
Hoore D.6
Penninckx, F.7
Vermeire, S.8
Rutgeerts, P.9
-
3
-
-
0037434552
-
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
-
Baert F., Noman M., Vermeire S., Van Assche G., D'Haens G., Carbonez A., and Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348 (2003) 601-608
-
(2003)
N. Engl. J. Med.
, vol.348
, pp. 601-608
-
-
Baert, F.1
Noman, M.2
Vermeire, S.3
Van Assche, G.4
D'Haens, G.5
Carbonez, A.6
Rutgeerts, P.7
-
4
-
-
0038184193
-
Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease
-
Baldassano R., Braegger C.P., Escher J.C., De Woody K., Hendricks D.F., Keenan G.F., and Winter H.S. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am. J. Gastroenterol. 8 4 (2003) 833-838
-
(2003)
Am. J. Gastroenterol.
, vol.8
, Issue.4
, pp. 833-838
-
-
Baldassano, R.1
Braegger, C.P.2
Escher, J.C.3
De Woody, K.4
Hendricks, D.F.5
Keenan, G.F.6
Winter, H.S.7
-
5
-
-
34248136340
-
Inflammatory bowel disease: clinical aspects and established and evolving therapies
-
Baumgart D.C., and Sandborn W.J. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Rev. Lancet 12 (2007) 1641-1657
-
(2007)
Rev. Lancet
, vol.12
, pp. 1641-1657
-
-
Baumgart, D.C.1
Sandborn, W.J.2
-
6
-
-
33644859927
-
Predictors of Crohn's disease
-
Beaugerie L., Seksik P., Nion-Larmurier I., Gendre J.P., and Cosnes J. Predictors of Crohn's disease. Gastroenterology 130 (2006) 650-656
-
(2006)
Gastroenterology
, vol.130
, pp. 650-656
-
-
Beaugerie, L.1
Seksik, P.2
Nion-Larmurier, I.3
Gendre, J.P.4
Cosnes, J.5
-
7
-
-
30944442404
-
Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study
-
Biancone L., Orlando A., Kohn A., Colombo E., Sostegni R., Angelucci E., Rizzello F., Castiglione F., Benazzato L., Papi C., Meucci G., Riegler G., Petruzziello C., Mocciaro F., Geremia A., Calabrese E., Cottone M., and Pallone F. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut 55 (2006) 228-233
-
(2006)
Gut
, vol.55
, pp. 228-233
-
-
Biancone, L.1
Orlando, A.2
Kohn, A.3
Colombo, E.4
Sostegni, R.5
Angelucci, E.6
Rizzello, F.7
Castiglione, F.8
Benazzato, L.9
Papi, C.10
Meucci, G.11
Riegler, G.12
Petruzziello, C.13
Mocciaro, F.14
Geremia, A.15
Calabrese, E.16
Cottone, M.17
Pallone, F.18
-
8
-
-
33646696885
-
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials
-
Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., and Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 (2006) 2275-2285
-
(2006)
JAMA
, vol.295
, pp. 2275-2285
-
-
Bongartz, T.1
Sutton, A.J.2
Sweeting, M.J.3
Buchan, I.4
Matteson, E.L.5
Montori, V.6
-
9
-
-
4544305960
-
Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease
-
Borrelli O., Bascietto C., Viola F., Bueno de Mesquita M., Barbato M., Mancini V., Bosco S., and Cucchiara S. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig. Liver Dis. 36 (2004) 342-347
-
(2004)
Dig. Liver Dis.
, vol.36
, pp. 342-347
-
-
Borrelli, O.1
Bascietto, C.2
Viola, F.3
Bueno de Mesquita, M.4
Barbato, M.5
Mancini, V.6
Bosco, S.7
Cucchiara, S.8
-
10
-
-
0037029430
-
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial
-
Braun J., Brandt J., Listing J., Zink A., Alten R., Golder W., Gronica-Ihle E., Kellner H., Krause A., Scneider M., Sorensen H., Zeidler H., Thriene W., and Sieper J. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359 (2002) 1187-1193
-
(2002)
Lancet
, vol.359
, pp. 1187-1193
-
-
Braun, J.1
Brandt, J.2
Listing, J.3
Zink, A.4
Alten, R.5
Golder, W.6
Gronica-Ihle, E.7
Kellner, H.8
Krause, A.9
Scneider, M.10
Sorensen, H.11
Zeidler, H.12
Thriene, W.13
Sieper, J.14
-
11
-
-
33645128368
-
Infliximab for the treatment of pyoderma gangrenosum: a randomised, double-blind, placebo controlled trial
-
Brooklyn T.N., Dunnill M.G.S., Shetty A., Bowden J.J., Williams J.D.L., Griffiths C.E.M., Forbes A., Greenwood R., and Probert C.S. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double-blind, placebo controlled trial. Gut 55 (2006) 505-509
-
(2006)
Gut
, vol.55
, pp. 505-509
-
-
Brooklyn, T.N.1
Dunnill, M.G.S.2
Shetty, A.3
Bowden, J.J.4
Williams, J.D.L.5
Griffiths, C.E.M.6
Forbes, A.7
Greenwood, R.8
Probert, C.S.9
-
12
-
-
12344329448
-
Ciclosporin use in acute ulcerative colitis: a long-term experience
-
Campbell S., Travis S., and Jewell D. Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur. J. Gastroenterol. Hepatol. 17 (2005) 79-84
-
(2005)
Eur. J. Gastroenterol. Hepatol.
, vol.17
, pp. 79-84
-
-
Campbell, S.1
Travis, S.2
Jewell, D.3
-
13
-
-
0028790186
-
A controlled double blind study of azathioprine in the management of Crohn's disease
-
Candy S., Wright J., Gerber M., Adams G., Gerig M., and Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 37 (1995) 674-678
-
(1995)
Gut
, vol.37
, pp. 674-678
-
-
Candy, S.1
Wright, J.2
Gerber, M.3
Adams, G.4
Gerig, M.5
Goodman, R.6
-
14
-
-
0141613187
-
A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (Remicade) in severe pediatric Crohn's disease
-
Cezard J.P., Nouaili N., Talbotec C., Hugot J.P., Gobert J.G., Schmiz J., Mougenot J.F., Alberti C., and Goulet O. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (Remicade) in severe pediatric Crohn's disease. J. Pediatr. Gastroenterol. Nutr. 36 (2003) 632-636
-
(2003)
J. Pediatr. Gastroenterol. Nutr.
, vol.36
, pp. 632-636
-
-
Cezard, J.P.1
Nouaili, N.2
Talbotec, C.3
Hugot, J.P.4
Gobert, J.G.5
Schmiz, J.6
Mougenot, J.F.7
Alberti, C.8
Goulet, O.9
-
15
-
-
0003059415
-
Infliximab for patients with refractory ulcerative colitis
-
Chey W.Y. Infliximab for patients with refractory ulcerative colitis. Inflamm. Bowel Dis. 7 (2001) S30
-
(2001)
Inflamm. Bowel Dis.
, vol.7
-
-
Chey, W.Y.1
-
16
-
-
0347991877
-
The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients
-
Colombel J.F., Loftus Jr. E.V., Tremaine W.J., Egan L.J., Harmsen W.S., Schleck C.D., Zinsmeister A.R., and Sandborn W.J. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 126 (2004) 19-31
-
(2004)
Gastroenterology
, vol.126
, pp. 19-31
-
-
Colombel, J.F.1
Loftus Jr., E.V.2
Tremaine, W.J.3
Egan, L.J.4
Harmsen, W.S.5
Schleck, C.D.6
Zinsmeister, A.R.7
Sandborn, W.J.8
-
17
-
-
2942668573
-
Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy
-
Colombel J.F., Loftus Jr. E.V., Tremaine W.J., Pemberton J.H., Wolff B.G., Young-Fadok T., Harmsen W.S., Schleck C.D., and Sandborn W.J. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am. J. Gastroenterol. 99 (2004) 878-883
-
(2004)
Am. J. Gastroenterol.
, vol.99
, pp. 878-883
-
-
Colombel, J.F.1
Loftus Jr., E.V.2
Tremaine, W.J.3
Pemberton, J.H.4
Wolff, B.G.5
Young-Fadok, T.6
Harmsen, W.S.7
Schleck, C.D.8
Sandborn, W.J.9
-
18
-
-
33846242958
-
Adalimumab induces and maintains clinical response and remission in patients with active Crohn's disease: the CHARM trial
-
Colombel J.F., Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Panaccione R., Schreiber S., Byczkowski D., Li J., and Kent J.D. Adalimumab induces and maintains clinical response and remission in patients with active Crohn's disease: the CHARM trial. Gastroenterology 132 (2007) 52-65
-
(2007)
Gastroenterology
, vol.132
, pp. 52-65
-
-
Colombel, J.F.1
Sandborn, W.J.2
Rutgeerts, P.3
Enns, R.4
Hanauer, S.B.5
Panaccione, R.6
Schreiber, S.7
Byczkowski, D.8
Li, J.9
Kent, J.D.10
-
19
-
-
17744373658
-
Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease
-
Cornillie F., Shealy D., D'Haens G., Geboes K., Van Assche G., Ceuppens J., Wagner C., Schaible T., Plevy S.E., Targan S.R., and Rutgeerts P. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment. Pharmacol. Ther. 15 (2001) 463-473
-
(2001)
Aliment. Pharmacol. Ther.
, vol.15
, pp. 463-473
-
-
Cornillie, F.1
Shealy, D.2
D'Haens, G.3
Geboes, K.4
Van Assche, G.5
Ceuppens, J.6
Wagner, C.7
Schaible, T.8
Plevy, S.E.9
Targan, S.R.10
Rutgeerts, P.11
-
20
-
-
0036061640
-
Long-term evolution of disease behavior of Crohn's disease
-
Cosnes J., Cattan S., Blain A., Beaugerie L., Carbonnel F., Parc R., and Gendre J.P. Long-term evolution of disease behavior of Crohn's disease. Inflamm. Bowel Dis. 8 (2002) 244-250
-
(2002)
Inflamm. Bowel Dis.
, vol.8
, pp. 244-250
-
-
Cosnes, J.1
Cattan, S.2
Blain, A.3
Beaugerie, L.4
Carbonnel, F.5
Parc, R.6
Gendre, J.P.7
-
21
-
-
0032723990
-
Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine
-
D'Haens G., Geboes K., and Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest. Endosc. 50 (1999) 667-671
-
(1999)
Gastrointest. Endosc.
, vol.50
, pp. 667-671
-
-
D'Haens, G.1
Geboes, K.2
Rutgeerts, P.3
-
22
-
-
39449085441
-
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial
-
D'Haens G., Baert F., van Assche G., Caenepeel P., Vergauwe P., Tuynman H., De Vos M., van Deventer S., Stitt L., Donner A., Vermeire S., van de Mierop F.J., Coche J.C.R., van der Woude J., Ochsenkuhn T., van Bodegrave A.A., Hootegem P.P., Lambrecht G.L., Mana F., Rutgeerts P., Feagan B.G., and Hommes D. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371 (2008) 660-667
-
(2008)
Lancet
, vol.371
, pp. 660-667
-
-
D'Haens, G.1
Baert, F.2
van Assche, G.3
Caenepeel, P.4
Vergauwe, P.5
Tuynman, H.6
De Vos, M.7
van Deventer, S.8
Stitt, L.9
Donner, A.10
Vermeire, S.11
van de Mierop, F.J.12
Coche, J.C.R.13
van der Woude, J.14
Ochsenkuhn, T.15
van Bodegrave, A.A.16
Hootegem, P.P.17
Lambrecht, G.L.18
Mana, F.19
Rutgeerts, P.20
Feagan, B.G.21
Hommes, D.22
more..
-
23
-
-
4744375545
-
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD
-
Daperno M., D'Haens G., and Van Assche G. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest. Endosc. 60 (2004) 505-512
-
(2004)
Gastrointest. Endosc.
, vol.60
, pp. 505-512
-
-
Daperno, M.1
D'Haens, G.2
Van Assche, G.3
-
24
-
-
21744446004
-
Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey
-
Club Rhumatismes et Inflammation
-
De Bandt M., Sibilia J., Le Loët X., Prouzeau S., Fautrel B., Marcelli C., Boucquillard E., Siame J.L., Mariette X., and Club Rhumatismes et Inflammation. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis. Res. Ther. 7 (2005) R545-551
-
(2005)
Arthritis. Res. Ther.
, vol.7
-
-
De Bandt, M.1
Sibilia, J.2
Le Loët, X.3
Prouzeau, S.4
Fautrel, B.5
Marcelli, C.6
Boucquillard, E.7
Siame, J.L.8
Mariette, X.9
-
25
-
-
1842632413
-
Anti-tumor necrosis factor alpha therapy and heart failure
-
Dinesh K., McMahon M., and Furst D.E. Anti-tumor necrosis factor alpha therapy and heart failure. Arthritis and Rheumatism 50 (2004) 1040-1050
-
(2004)
Arthritis and Rheumatism
, vol.50
, pp. 1040-1050
-
-
Dinesh, K.1
McMahon, M.2
Furst, D.E.3
-
26
-
-
0037379792
-
Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial
-
Farrell R.J., Alsahli M., Jeen Y.T., Falchuk K.R., Peppercorn M.A., and Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 124 (2003) 917-924
-
(2003)
Gastroenterology
, vol.124
, pp. 917-924
-
-
Farrell, R.J.1
Alsahli, M.2
Jeen, Y.T.3
Falchuk, K.R.4
Peppercorn, M.A.5
Michetti, P.6
-
27
-
-
0034903792
-
The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study
-
Faubion Jr. W.A., Loftus Jr. E.V., Harmsen W.S., Zinsmeister A.R., and Sandborn W.J. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121 (2001) 255-260
-
(2001)
Gastroenterology
, vol.121
, pp. 255-260
-
-
Faubion Jr., W.A.1
Loftus Jr., E.V.2
Harmsen, W.S.3
Zinsmeister, A.R.4
Sandborn, W.J.5
-
28
-
-
0028899859
-
Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators
-
Feagan B.G., Rochon J., Fedorak R.N., Irvine E.J., Wild G., Sutherland L., Steinhart A.H., Greenberg G.R., Gillies R., Hopkins M., Hanauer S.B., and McDonald J.W.D. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N. Eng. J. Med. 332 (1995) 292-297
-
(1995)
N. Eng. J. Med.
, vol.332
, pp. 292-297
-
-
Feagan, B.G.1
Rochon, J.2
Fedorak, R.N.3
Irvine, E.J.4
Wild, G.5
Sutherland, L.6
Steinhart, A.H.7
Greenberg, G.R.8
Gillies, R.9
Hopkins, M.10
Hanauer, S.B.11
McDonald, J.W.D.12
-
29
-
-
0034214336
-
A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators
-
Feagan B.G., Fedorak R.N., and Irvine E.J. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N. Engl. J. Med. 342 (2000) 1627-1632
-
(2000)
N. Engl. J. Med.
, vol.342
, pp. 1627-1632
-
-
Feagan, B.G.1
Fedorak, R.N.2
Irvine, E.J.3
-
30
-
-
69449087793
-
Corticosteroids but not Infliximab Increase Short-term Infectious Complications in patients with Ulcerative Colitis
-
(Electronic publication ahead of print)
-
Ferrante M., D'Hoore A., Vermeire S., Declerck S., Noman M., Van Assche G., Hoffman I., Rutgeerts P., and Penninckx F. Corticosteroids but not Infliximab Increase Short-term Infectious Complications in patients with Ulcerative Colitis. Inflamm. Bowel Dis. (2009) (Electronic publication ahead of print)
-
(2009)
Inflamm. Bowel Dis.
-
-
Ferrante, M.1
D'Hoore, A.2
Vermeire, S.3
Declerck, S.4
Noman, M.5
Van Assche, G.6
Hoffman, I.7
Rutgeerts, P.8
Penninckx, F.9
-
31
-
-
63849251824
-
Long term safety of infliximab for the treatment of inflammatory bowel disease: a single center cohort study
-
Fidder H., Schnitzler F., Ferrante M., Noman M., Katsanos K., Segaert S., Henkaerts L., Van Assche G., Vermeire S., and Rutgeerts P. Long term safety of infliximab for the treatment of inflammatory bowel disease: a single center cohort study. Gut 58 (2009) 501-508
-
(2009)
Gut
, vol.58
, pp. 501-508
-
-
Fidder, H.1
Schnitzler, F.2
Ferrante, M.3
Noman, M.4
Katsanos, K.5
Segaert, S.6
Henkaerts, L.7
Van Assche, G.8
Vermeire, S.9
Rutgeerts, P.10
-
32
-
-
34547503869
-
Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort
-
Ibsen Group
-
Frøslie K.F., Jahnsen J., Moum B.A., Vatn M.H., and Ibsen Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 133 (2007) 412-422
-
(2007)
Gastroenterology.
, vol.133
, pp. 412-422
-
-
Frøslie, K.F.1
Jahnsen, J.2
Moum, B.A.3
Vatn, M.H.4
-
33
-
-
0037007683
-
Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha
-
Gorman J., Sack K., and Davis J. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N. Engl. J. Med. 346 (2002) 1349-1356
-
(2002)
N. Engl. J. Med.
, vol.346
, pp. 1349-1356
-
-
Gorman, J.1
Sack, K.2
Davis, J.3
-
34
-
-
24144479466
-
Increased risk for demyelinating diseases in patients with inflammatory bowel disease
-
Gupta G., Gelfand J.M., and Lewis J.D. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology 129 (2005) 819-826
-
(2005)
Gastroenterology
, vol.129
, pp. 819-826
-
-
Gupta, G.1
Gelfand, J.M.2
Lewis, J.D.3
-
35
-
-
0037018761
-
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
-
Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., Rachmilewitz D., Wolf D.C., Olson A., Bao W., and Rutgeerts P. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
-
(2002)
Lancet
, vol.359
, pp. 1541-1549
-
-
Hanauer, S.B.1
Feagan, B.G.2
Lichtenstein, G.R.3
Mayer, L.F.4
Schreiber, S.5
Colombel, J.F.6
Rachmilewitz, D.7
Wolf, D.C.8
Olson, A.9
Bao, W.10
Rutgeerts, P.11
-
36
-
-
3042579454
-
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease
-
Hanauer S.B., Wagner C.L., and Bala M. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin. Gastroenterol. Hepatol. 2 (2004) 542-553
-
(2004)
Clin. Gastroenterol. Hepatol.
, vol.2
, pp. 542-553
-
-
Hanauer, S.B.1
Wagner, C.L.2
Bala, M.3
-
37
-
-
56449114364
-
A. randomized, double-blind, placebo-controlled trial of the human anti-TNF-a monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn's disease
-
Hanauer S., Lukáš M., MacIntosh D., Rutgeerts P., Sandborn W., and Pollack P. A. randomized, double-blind, placebo-controlled trial of the human anti-TNF-a monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn's disease. Gastroenterology 130 (2006) 323-333
-
(2006)
Gastroenterology
, vol.130
, pp. 323-333
-
-
Hanauer, S.1
Lukáš, M.2
MacIntosh, D.3
Rutgeerts, P.4
Sandborn, W.5
Pollack, P.6
-
38
-
-
33947397636
-
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children
-
REACH Study Group
-
Hyams J., Crandall W., Kugathasan S., Griffiths A., Olson A., Johanns J., Liu G., Travers S., Heuschkel R., Markowitz J., Cohen S., Winter H., Veereman-Wouters G., Ferry G., Baldassano R., and REACH Study Group. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 132 (2007) 863-873
-
(2007)
Gastroenterology
, vol.132
, pp. 863-873
-
-
Hyams, J.1
Crandall, W.2
Kugathasan, S.3
Griffiths, A.4
Olson, A.5
Johanns, J.6
Liu, G.7
Travers, S.8
Heuschkel, R.9
Markowitz, J.10
Cohen, S.11
Winter, H.12
Veereman-Wouters, G.13
Ferry, G.14
Baldassano, R.15
-
39
-
-
20444479336
-
Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study
-
Jarnerot G., Hertervig E., Friis-Liby I., Blomquist L., Karlen P., Granno C., Vilien M., Strom M., Danielsson A., Verbaan H., Hellstrom P.M., Magnuson A., and Curman B. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128 (2005) 1805-1811
-
(2005)
Gastroenterology
, vol.128
, pp. 1805-1811
-
-
Jarnerot, G.1
Hertervig, E.2
Friis-Liby, I.3
Blomquist, L.4
Karlen, P.5
Granno, C.6
Vilien, M.7
Strom, M.8
Danielsson, A.9
Verbaan, H.10
Hellstrom, P.M.11
Magnuson, A.12
Curman, B.13
-
40
-
-
0035846326
-
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent
-
Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., Siegel J.N., and Braun M.M. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 345 (2001) 1098-1104
-
(2001)
N. Engl. J. Med.
, vol.345
, pp. 1098-1104
-
-
Keane, J.1
Gershon, S.2
Wise, R.P.3
Mirabile-Levens, E.4
Kasznica, J.5
Schwieterman, W.D.6
Siegel, J.N.7
Braun, M.M.8
-
41
-
-
71549120544
-
Successive treatment with cyclosporine and infliximab in severe ulcerative colitis (UC)
-
A-88
-
Leblanc S., Allez M., and Seksik P. Successive treatment with cyclosporine and infliximab in severe ulcerative colitis (UC). Gastroenterology 136 (2009) A-88
-
(2009)
Gastroenterology
, vol.136
-
-
Leblanc, S.1
Allez, M.2
Seksik, P.3
-
42
-
-
20444483170
-
A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine
-
Lemann M., Mary J.Y., Colombel J.F., Duclos B., Soule J.C., Lerebours E., Modigliani R., and Bouhnik Y. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 128 (2006) 1812-1818
-
(2006)
Gastroenterology
, vol.128
, pp. 1812-1818
-
-
Lemann, M.1
Mary, J.Y.2
Colombel, J.F.3
Duclos, B.4
Soule, J.C.5
Lerebours, E.6
Modigliani, R.7
Bouhnik, Y.8
-
43
-
-
0034764110
-
Inflammatory bowel disease is not associated with an increased risk of lymphoma
-
Lewis J.D., Bilker W.B., Brensinger C., Deren J.J., Vaughn D.J., and Storm B.L. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 121 (2001) 1080-1087
-
(2001)
Gastroenterology
, vol.121
, pp. 1080-1087
-
-
Lewis, J.D.1
Bilker, W.B.2
Brensinger, C.3
Deren, J.J.4
Vaughn, D.J.5
Storm, B.L.6
-
44
-
-
29144492201
-
Safety of infliximab and other Crohn's disease therapies - updated Treat registry data with over 10,000 patient-years of follow-up
-
A-580 (Abstract)
-
Lichtenstein G.R., Cohen R.D., and Feagan B.G. Safety of infliximab and other Crohn's disease therapies - updated Treat registry data with over 10,000 patient-years of follow-up. Gastroenterology 128 (2005) A-580 (Abstract)
-
(2005)
Gastroenterology
, vol.128
-
-
Lichtenstein, G.R.1
Cohen, R.D.2
Feagan, B.G.3
-
45
-
-
17144388945
-
Infliximab maintenance treatment reduces hospitalizations, surgeries and procedures in fistulizing Crohn's disease
-
Lichtenstein G.R., Yan S., Bala M., Blank M., and Sands B.E. Infliximab maintenance treatment reduces hospitalizations, surgeries and procedures in fistulizing Crohn's disease. Gastroenterology 128 (2005) 862-869
-
(2005)
Gastroenterology
, vol.128
, pp. 862-869
-
-
Lichtenstein, G.R.1
Yan, S.2
Bala, M.3
Blank, M.4
Sands, B.E.5
-
46
-
-
0028292007
-
Cyclosporine in severe ulcerative colitis refractory to steroid therapy
-
Lichtiger S., Present D.H., Kornbluth A., Gelernt I., Bauer J., Galler G., Michelassi F., and Hanauer S. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N. Eng. J. Med. 330 (1994) 1841-1845
-
(1994)
N. Eng. J. Med.
, vol.330
, pp. 1841-1845
-
-
Lichtiger, S.1
Present, D.H.2
Kornbluth, A.3
Gelernt, I.4
Bauer, J.5
Galler, G.6
Michelassi, F.7
Hanauer, S.8
-
48
-
-
70349384546
-
Infliximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors: a prospective ongoing cohort study
-
A-146
-
Louis E., Vernier-Massouille G., and Grimaud J.C. Infliximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors: a prospective ongoing cohort study. Gastroenterology 136 (2009) A-146
-
(2009)
Gastroenterology
, vol.136
-
-
Louis, E.1
Vernier-Massouille, G.2
Grimaud, J.C.3
-
49
-
-
33846592386
-
Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease
-
Mackey A.C., Green L., Liang L.C., Dinndorf P., and Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J. Ped. Gastroenterology & Nutrition 44 (2007) 265-267
-
(2007)
J. Ped. Gastroenterology & Nutrition
, vol.44
, pp. 265-267
-
-
Mackey, A.C.1
Green, L.2
Liang, L.C.3
Dinndorf, P.4
Avigan, M.5
-
50
-
-
16344369052
-
Intentional infliximab use during pregnancy for induction or maintenance of remission of Crohn's Disease
-
Mahadevan U., Kane S., and Sandborn W.J. Intentional infliximab use during pregnancy for induction or maintenance of remission of Crohn's Disease. Aliment. Pharmacol. Ther. 21 (2005) 733-738
-
(2005)
Aliment. Pharmacol. Ther.
, vol.21
, pp. 733-738
-
-
Mahadevan, U.1
Kane, S.2
Sandborn, W.J.3
-
51
-
-
11144357651
-
The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study
-
Marchal L., D'Haens G., Van Assche G., Vermeire S., Noman M., Ferrante M., Hiele M., Bueno De Mesquita M., D'Hoore A., Penninckx F., and Rutgeerts P. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment. Pharmacol. Ther. 19 (2004) 749-754
-
(2004)
Aliment. Pharmacol. Ther.
, vol.19
, pp. 749-754
-
-
Marchal, L.1
D'Haens, G.2
Van Assche, G.3
Vermeire, S.4
Noman, M.5
Ferrante, M.6
Hiele, M.7
Bueno De Mesquita, M.8
D'Hoore, A.9
Penninckx, F.10
Rutgeerts, P.11
-
52
-
-
33748147712
-
Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease
-
for the Pediatric IBD Collaborative Research Group
-
Markowitz J., Hyams J., Mack D., Leleiko N., Evans J., Kugathasan S., Pfefferkorn M., Mezoff A., Rosh N., Vasundhara T., Otley A., Griffiths A., Moyer M.S., Oliva-Hemker M., Wyllie R., Rothbaum R., Bousvaros A., Del Rosario J.F., Hale S., Lerer T., and for the Pediatric IBD Collaborative Research Group. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease. Clin. Gastroenterol. Hepatol. 4 (2006) 1124-1129
-
(2006)
Clin. Gastroenterol. Hepatol.
, vol.4
, pp. 1124-1129
-
-
Markowitz, J.1
Hyams, J.2
Mack, D.3
Leleiko, N.4
Evans, J.5
Kugathasan, S.6
Pfefferkorn, M.7
Mezoff, A.8
Rosh, N.9
Vasundhara, T.10
Otley, A.11
Griffiths, A.12
Moyer, M.S.13
Oliva-Hemker, M.14
Wyllie, R.15
Rothbaum, R.16
Bousvaros, A.17
Del Rosario, J.F.18
Hale, S.19
Lerer, T.20
more..
-
53
-
-
0001607738
-
Development and validation of an endoscopic index of the severity of Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID)
-
Mary J.Y., and Modigliani R. Development and validation of an endoscopic index of the severity of Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 30 (1989) 983-989
-
(1989)
Gut
, vol.30
, pp. 983-989
-
-
Mary, J.Y.1
Modigliani, R.2
-
54
-
-
33749432435
-
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease
-
Maser E.A., Villela R., Silverberg M.S., and Greenberg G.R. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin. Gastroenterol. Hepatol. 4 (2006) 1248-1254
-
(2006)
Clin. Gastroenterol. Hepatol.
, vol.4
, pp. 1248-1254
-
-
Maser, E.A.1
Villela, R.2
Silverberg, M.S.3
Greenberg, G.R.4
-
55
-
-
44949098949
-
Cyclosporine (CsA) and infliximab (Infl) as acute salvage therapies for each other in severe steroid refractory ulcerative colitis (UC)
-
A-180
-
Maser E., Deconda D., Lichtiger S., Present D., and Kornbluth A. Cyclosporine (CsA) and infliximab (Infl) as acute salvage therapies for each other in severe steroid refractory ulcerative colitis (UC). Gastroenterology 132 (2007) A-180
-
(2007)
Gastroenterology
, vol.132
-
-
Maser, E.1
Deconda, D.2
Lichtiger, S.3
Present, D.4
Kornbluth, A.5
-
56
-
-
0025219580
-
Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone
-
and the Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
-
Modigliani R., Mary J.Y., Simon J.F., Cortot A., Soule J.C., Gendre J.P., Rene E., and and the Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Gastroenterology 98 (1990) 811-818
-
(1990)
Gastroenterology
, vol.98
, pp. 811-818
-
-
Modigliani, R.1
Mary, J.Y.2
Simon, J.F.3
Cortot, A.4
Soule, J.C.5
Gendre, J.P.6
Rene, E.7
-
57
-
-
33744832164
-
Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis
-
Moskovitz D.N., Van Assche G., Maenhout B., Arts J., Ferrante M., Vermeire S., and Rutgeerts P. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin. Gastroenterol. Hepatol. 4 (2006) 760-765
-
(2006)
Clin. Gastroenterol. Hepatol.
, vol.4
, pp. 760-765
-
-
Moskovitz, D.N.1
Van Assche, G.2
Maenhout, B.3
Arts, J.4
Ferrante, M.5
Vermeire, S.6
Rutgeerts, P.7
-
58
-
-
0028267896
-
Frequency of glucocorticoid resistance and dependency in Crohn's disease
-
Munkholm P., Langholz E., Davidsen M., and Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 35 (1994) 360-362
-
(1994)
Gut
, vol.35
, pp. 360-362
-
-
Munkholm, P.1
Langholz, E.2
Davidsen, M.3
Binder, V.4
-
59
-
-
0025322362
-
Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation
-
Olaison G., Sjodahl R., and Tagesson C. Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation. Gut 31 (1990) 325-328
-
(1990)
Gut
, vol.31
, pp. 325-328
-
-
Olaison, G.1
Sjodahl, R.2
Tagesson, C.3
-
60
-
-
44649187924
-
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials
-
Peyrin-Biroulet L., Delterne P., De Suray N., Branche J., Sandborn W., and Colombel J.F. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin. Gastroenter. Hepatol. 6 (2008) 644-653
-
(2008)
Clin. Gastroenter. Hepatol.
, vol.6
, pp. 644-653
-
-
Peyrin-Biroulet, L.1
Delterne, P.2
De Suray, N.3
Branche, J.4
Sandborn, W.5
Colombel, J.F.6
-
61
-
-
0018888679
-
Treatment of Crohn's disease with S-mercaptopurine. A long-term randomized, double-blind study
-
Present D.H., Korelitz B.I., Wisch N., Glass J.L., Sachar D.B., and Pasternack B.S. Treatment of Crohn's disease with S-mercaptopurine. A long-term randomized, double-blind study. N. Eng. J. Med. 302 (1980) 981-987
-
(1980)
N. Eng. J. Med.
, vol.302
, pp. 981-987
-
-
Present, D.H.1
Korelitz, B.I.2
Wisch, N.3
Glass, J.L.4
Sachar, D.B.5
Pasternack, B.S.6
-
62
-
-
0033529049
-
Infliximab for the treatment of fistulas in patients with Crohn's disease
-
Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., van Hogezand R.A., Podolsky D.K., Sands B.E., Braakman T., DeWoody K.L., Schaible T.F., and van Deventer S.J.H. Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 340 (1999) 1398-1405
-
(1999)
N. Engl. J. Med.
, vol.340
, pp. 1398-1405
-
-
Present, D.H.1
Rutgeerts, P.2
Targan, S.3
Hanauer, S.B.4
Mayer, L.5
van Hogezand, R.A.6
Podolsky, D.K.7
Sands, B.E.8
Braakman, T.9
DeWoody, K.L.10
Schaible, T.F.11
van Deventer, S.J.H.12
-
63
-
-
33748260362
-
Infliximab for hospitalized patients with severe ulcerative colitis
-
Regueiro M., Curtis J., and Plevy S. Infliximab for hospitalized patients with severe ulcerative colitis. J. Clin. Gastroenterol. 40 (2006) 476-481
-
(2006)
J. Clin. Gastroenterol.
, vol.40
, pp. 476-481
-
-
Regueiro, M.1
Curtis, J.2
Plevy, S.3
-
64
-
-
34347369156
-
Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?
-
Rosh J.R., et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?. Inflamm. Bowel Dis. 13 (2007) 1024-1030
-
(2007)
Inflamm. Bowel Dis.
, vol.13
, pp. 1024-1030
-
-
Rosh, J.R.1
-
65
-
-
0032833517
-
Efficacy and safety of Retreatment with Anti-Tumor Necrosis Factor Antibody (Infliximab) to Maintain Remission in Crohn's Disease
-
Rutgeerts P., D'Haens G., Targan S., Vasiliauskas E., Hanauer S.B., Present D.H., Mayer L., van Hogezand R., Braakman T., DeWoody K.L., Schaible T.F., and van Deventer S.J.H. Efficacy and safety of Retreatment with Anti-Tumor Necrosis Factor Antibody (Infliximab) to Maintain Remission in Crohn's Disease. Gastroenterology 117 (1999) 761-769
-
(1999)
Gastroenterology
, vol.117
, pp. 761-769
-
-
Rutgeerts, P.1
D'Haens, G.2
Targan, S.3
Vasiliauskas, E.4
Hanauer, S.B.5
Present, D.H.6
Mayer, L.7
van Hogezand, R.8
Braakman, T.9
DeWoody, K.L.10
Schaible, T.F.11
van Deventer, S.J.H.12
-
66
-
-
10744224387
-
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease
-
Rutgeerts P., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., Rachmilewitz D., Wolf D.C., Olson A., Bao W., and Hanauer S.B. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126 (2004) 402-413
-
(2004)
Gastroenterology
, vol.126
, pp. 402-413
-
-
Rutgeerts, P.1
Feagan, B.G.2
Lichtenstein, G.R.3
Mayer, L.F.4
Schreiber, S.5
Colombel, J.F.6
Rachmilewitz, D.7
Wolf, D.C.8
Olson, A.9
Bao, W.10
Hanauer, S.B.11
-
67
-
-
28844473957
-
Infliximab for induction and maintenance therapy for ulcerative colitis
-
Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., Travers S., Rachmilewitz D., Hanauer S.B., Lichtenstein G.R., de Villers W.J.S., Present D., Sands B.E., and Colombel J.F. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353 (2005) 2462-2476
-
(2005)
N. Engl. J. Med.
, vol.353
, pp. 2462-2476
-
-
Rutgeerts, P.1
Sandborn, W.J.2
Feagan, B.G.3
Reinisch, W.4
Olson, A.5
Johanns, J.6
Travers, S.7
Rachmilewitz, D.8
Hanauer, S.B.9
Lichtenstein, G.R.10
de Villers, W.J.S.11
Present, D.12
Sands, B.E.13
Colombel, J.F.14
-
68
-
-
32944461717
-
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease
-
Rutgeerts P., Diamond R.H., Bala M., Olson A., Lichtenstein G.R., Bao W., Patel K., Wolf D.C., Safdi M., Colombel J.F., Lashner B., and Hanauer S.B. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest. Endosc. 63 (2006) 433-442
-
(2006)
Gastrointest. Endosc.
, vol.63
, pp. 433-442
-
-
Rutgeerts, P.1
Diamond, R.H.2
Bala, M.3
Olson, A.4
Lichtenstein, G.R.5
Bao, W.6
Patel, K.7
Wolf, D.C.8
Safdi, M.9
Colombel, J.F.10
Lashner, B.11
Hanauer, S.B.12
-
70
-
-
34447523749
-
Certolizumab pegol for the treatment of Crohn's disease
-
PRECISE 1 Study Investigators
-
Sandborn W.J., Feagan B.G., Stoinov S., Honiball P.J., Rutgeerts P., Mason D., Bloomfield R., Schreiber S., and PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn's disease. N. Engl. J. Med. 357 (2007) 228-238
-
(2007)
N. Engl. J. Med.
, vol.357
, pp. 228-238
-
-
Sandborn, W.J.1
Feagan, B.G.2
Stoinov, S.3
Honiball, P.J.4
Rutgeerts, P.5
Mason, D.6
Bloomfield, R.7
Schreiber, S.8
-
71
-
-
34249281002
-
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
-
Sandborn W.J., Hanauer S.B., Rutgeerts P.J., Fedorak R.N., Lukas M., MacIntosh D.G., Pannacione R., Wolf D., Kent J.D., Bittle B., Li J., and Pollack P.F. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 6 (2007) 1232-1239
-
(2007)
Gut
, vol.6
, pp. 1232-1239
-
-
Sandborn, W.J.1
Hanauer, S.B.2
Rutgeerts, P.J.3
Fedorak, R.N.4
Lukas, M.5
MacIntosh, D.G.6
Pannacione, R.7
Wolf, D.8
Kent, J.D.9
Bittle, B.10
Li, J.11
Pollack, P.F.12
-
72
-
-
34347402306
-
Adalimumab induction therapy for Crohn's disease previously treated with infliximab
-
Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Colombel J.F., Pannacione R., D'Haens G., Li J., Rosenfeld M.R., Kent J.D., and Pollack P.F. Adalimumab induction therapy for Crohn's disease previously treated with infliximab. Ann. Int. Med. 146 (2007) 829-838
-
(2007)
Ann. Int. Med.
, vol.146
, pp. 829-838
-
-
Sandborn, W.J.1
Rutgeerts, P.2
Enns, R.3
Hanauer, S.B.4
Colombel, J.F.5
Pannacione, R.6
D'Haens, G.7
Li, J.8
Rosenfeld, M.R.9
Kent, J.D.10
Pollack, P.F.11
-
73
-
-
55249088369
-
SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy
-
abstract
-
abstract. Sandborn W.J., Rutgeerts P., and Reinisch W. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Am. J. Gastroenterology 103 (2008) S436
-
(2008)
Am. J. Gastroenterology
, vol.103
-
-
Sandborn, W.J.1
Rutgeerts, P.2
Reinisch, W.3
-
74
-
-
70349418632
-
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab
-
Sandborn W.J., Rutgeerts P., Feagan B.G., Reinisch W., Olson A., Johanns J., Lu J., Horgan K., Rachmilewitz D., Hanauer S.B., Lichtenstein G.R., de Villers W.J.S., Present D., Sands B.E., and Colombel J.F. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 137 (2009) 1250-1260
-
(2009)
Gastroenterology
, vol.137
, pp. 1250-1260
-
-
Sandborn, W.J.1
Rutgeerts, P.2
Feagan, B.G.3
Reinisch, W.4
Olson, A.5
Johanns, J.6
Lu, J.7
Horgan, K.8
Rachmilewitz, D.9
Hanauer, S.B.10
Lichtenstein, G.R.11
de Villers, W.J.S.12
Present, D.13
Sands, B.E.14
Colombel, J.F.15
-
75
-
-
10744221312
-
Infliximab maintenance therapy for fistulizing Crohn's disease
-
Sands B.E., Anderson F.H., Bernstein C.N., Chey W.Y., Feagan B.G., Fedorak R.N., Kamm M.A., Korzenik J.R., Lashner B.A., Onken J.E., Rachnmilewitz D., Rutgeerts P., Wild G., Wolf D.C., Marsters P.A., Travers S.B., Blank M.A., and van Deventer S.J. Infliximab maintenance therapy for fistulizing Crohn's disease. N. Engl. J. Med. 350 (2004) 876-885
-
(2004)
N. Engl. J. Med.
, vol.350
, pp. 876-885
-
-
Sands, B.E.1
Anderson, F.H.2
Bernstein, C.N.3
Chey, W.Y.4
Feagan, B.G.5
Fedorak, R.N.6
Kamm, M.A.7
Korzenik, J.R.8
Lashner, B.A.9
Onken, J.E.10
Rachnmilewitz, D.11
Rutgeerts, P.12
Wild, G.13
Wolf, D.C.14
Marsters, P.A.15
Travers, S.B.16
Blank, M.A.17
van Deventer, S.J.18
-
76
-
-
70350172248
-
Mucosal healing predicts long-term outcome, of maintenance therapy with infliximab in Crohn's disease
-
Electronic publication
-
Schnitzler F., Fidder H., Ferrante M., Noman M., Arijs I., Van Assche G., Hoffman I., van Steen K., Vermeire S., and Rutgeerts P. Mucosal healing predicts long-term outcome, of maintenance therapy with infliximab in Crohn's disease. Inflamm. Bowel Dis. (2009) Electronic publication
-
(2009)
Inflamm. Bowel Dis.
-
-
Schnitzler, F.1
Fidder, H.2
Ferrante, M.3
Noman, M.4
Arijs, I.5
Van Assche, G.6
Hoffman, I.7
van Steen, K.8
Vermeire, S.9
Rutgeerts, P.10
-
77
-
-
63849101007
-
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort
-
Schnitzler F., Fidder H., Ferrante M., Noman M., Arijs I., Van Assche G., Hoffman I., Van Steen K., Vermeire S., and Rutgeerts P. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 58 (2009) 492-500
-
(2009)
Gut
, vol.58
, pp. 492-500
-
-
Schnitzler, F.1
Fidder, H.2
Ferrante, M.3
Noman, M.4
Arijs, I.5
Van Assche, G.6
Hoffman, I.7
Van Steen, K.8
Vermeire, S.9
Rutgeerts, P.10
-
78
-
-
24144483087
-
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease
-
the CDP870 Crohn's Disease Study Group
-
Schreiber S., Rutgeerts P., Fedorak R.N., Khaliq-Kareemi M., Kamm M., Boivn M., Bernstein N., Staun M., Ostergaard Thomsen O., Innes A., and the CDP870 Crohn's Disease Study Group. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129 (2005) 807-818
-
(2005)
Gastroenterology
, vol.129
, pp. 807-818
-
-
Schreiber, S.1
Rutgeerts, P.2
Fedorak, R.N.3
Khaliq-Kareemi, M.4
Kamm, M.5
Boivn, M.6
Bernstein, N.7
Staun, M.8
Ostergaard Thomsen, O.9
Innes, A.10
-
79
-
-
34447515607
-
Maintenance therapy with certolizumab pegol for Crohn's disease
-
for the PRECISE 2 Study Investigators
-
Schreiber S., Khaliq-Kareemi M., Lawrance I.C., Ostergaard Thomsen O., Hanauer S.B., McColm J., Bloomfield R., Sandborn W.J., and for the PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn's disease. N. Engl. J. Med. 357 (2007) 239-250
-
(2007)
N. Engl. J. Med.
, vol.357
, pp. 239-250
-
-
Schreiber, S.1
Khaliq-Kareemi, M.2
Lawrance, I.C.3
Ostergaard Thomsen, O.4
Hanauer, S.B.5
McColm, J.6
Bloomfield, R.7
Sandborn, W.J.8
-
80
-
-
0023521441
-
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study
-
Schroeder K.W., Tremaine W.J., and Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med. 317 (1987) 1625-1629
-
(1987)
N. Engl. J. Med.
, vol.317
, pp. 1625-1629
-
-
Schroeder, K.W.1
Tremaine, W.J.2
Ilstrup, D.M.3
-
81
-
-
34247469242
-
Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis
-
Selvasekar C.R., Cima R.R., Larson D.W., Dozois E.J., Harrngton J.R., Harmsen W.S., Loftus E.V., Sandborn W.J., Wolf B.C., and Pemberton J.H. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J. Am. Coll. Surg. 204 (2007) 956-963
-
(2007)
J. Am. Coll. Surg.
, vol.204
, pp. 956-963
-
-
Selvasekar, C.R.1
Cima, R.R.2
Larson, D.W.3
Dozois, E.J.4
Harrngton, J.R.5
Harmsen, W.S.6
Loftus, E.V.7
Sandborn, W.J.8
Wolf, B.C.9
Pemberton, J.H.10
-
82
-
-
0034911830
-
Use of infliximab in pediatric patients with inflammatory bowel disease
-
Serrano M.S., Schmidt-Sommerfeld E., Kilbaugh T.J., Brown R.F., Udall J.N., and Mannick E.E. Use of infliximab in pediatric patients with inflammatory bowel disease. Ann. Pharmacother. 35 (2001) 823-828
-
(2001)
Ann. Pharmacother.
, vol.35
, pp. 823-828
-
-
Serrano, M.S.1
Schmidt-Sommerfeld, E.2
Kilbaugh, T.J.3
Brown, R.F.4
Udall, J.N.5
Mannick, E.E.6
-
83
-
-
46749137801
-
Risk of lymphoma associated with anti-TNF agents for the treatment of Crohn's disease: a meta-analysis
-
A-144
-
A-144. Siegel C. Risk of lymphoma associated with anti-TNF agents for the treatment of Crohn's disease: a meta-analysis. Gastroenterology (2008)
-
(2008)
Gastroenterology
-
-
Siegel, C.1
-
84
-
-
67049137968
-
Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study)
-
Solberg I.C., Lygren I., and Jahnsen J. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand. J. Gastroenterol. 44 (2009) 431-440
-
(2009)
Scand. J. Gastroenterol.
, vol.44
, pp. 431-440
-
-
Solberg, I.C.1
Lygren, I.2
Jahnsen, J.3
-
85
-
-
0036269445
-
The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial
-
St Clair E.W., Wagner C.L., and Fasanmade A.A. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism. 46 (2002) 1451-1459
-
(2002)
Arthritis and Rheumatism.
, vol.46
, pp. 1451-1459
-
-
St Clair, E.W.1
Wagner, C.L.2
Fasanmade, A.A.3
-
86
-
-
0030954732
-
A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor a for Crohn's Disese
-
for the Crohn's Disease cA2 Study Group
-
Targan S.R., Hanauer S.B., van Deventer S.J.H., Mayer L., Present D., Braakman T., DeWoody K.L., Schaible T.F., Rutgeerts P.J., and for the Crohn's Disease cA2 Study Group. A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor a for Crohn's Disese. New Engl. J. Med. 337 (1997) 1029-1035
-
(1997)
New Engl. J. Med.
, vol.337
, pp. 1029-1035
-
-
Targan, S.R.1
Hanauer, S.B.2
van Deventer, S.J.H.3
Mayer, L.4
Present, D.5
Braakman, T.6
DeWoody, K.L.7
Schaible, T.F.8
Rutgeerts, P.J.9
-
87
-
-
41349088375
-
Risk factors for opportunistic infections in patients with inflammatory bowel disease
-
Toruner M., Loftus Jr. E.V., Harmsen W.S., Zinsmeister A.R., Orenstein R., Sandborn W.J., Colombel J.F., and Egan L.J. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 134 (2008) 929-936
-
(2008)
Gastroenterology
, vol.134
, pp. 929-936
-
-
Toruner, M.1
Loftus Jr., E.V.2
Harmsen, W.S.3
Zinsmeister, A.R.4
Orenstein, R.5
Sandborn, W.J.6
Colombel, J.F.7
Egan, L.J.8
-
88
-
-
33144459948
-
European evidence based consensus on the diagnosis and management of Crohn's disease: current management
-
for the European Crohn's and Colitis Organisation (ECCO)
-
Travis S.P., Stange E.F., Lémann M., Oresland T., Chowers Y., Forbes A., D'Haens G., Kitis G., Cortot A., Prantera C., Marteau P., Colombel J.F., Gionchetti P., Bouhnik Y., Tiret E., Kroesen J., Starlinger M., Mortensen N.J., and for the European Crohn's and Colitis Organisation (ECCO). European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 55 Suppl. 1 (2006) i16-35
-
(2006)
Gut 55 Suppl.
, vol.1
-
-
Travis, S.P.1
Stange, E.F.2
Lémann, M.3
Oresland, T.4
Chowers, Y.5
Forbes, A.6
D'Haens, G.7
Kitis, G.8
Cortot, A.9
Prantera, C.10
Marteau, P.11
Colombel, J.F.12
Gionchetti, P.13
Bouhnik, Y.14
Tiret, E.15
Kroesen, J.16
Starlinger, M.17
Mortensen, N.J.18
-
89
-
-
10744231879
-
Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis
-
Van Assche G., D'Haens G., Noman M., Vermeire S., Hiele M., Asnong K., Arts J., D'Hoore A., Penninckx F., and Rutgeerts P. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 125 (2003) 1025-1031
-
(2003)
Gastroenterology
, vol.125
, pp. 1025-1031
-
-
Van Assche, G.1
D'Haens, G.2
Noman, M.3
Vermeire, S.4
Hiele, M.5
Asnong, K.6
Arts, J.7
D'Hoore, A.8
Penninckx, F.9
Rutgeerts, P.10
-
90
-
-
0037282938
-
Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease
-
Van Assche G., Vanbeckevoort D., Bielen D., Coremans G., Aerden I., Noman M., D'Hoore A., Penninckx F., Marchal G., Cornillie F., and Rutgeerts P. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am. J. Gastroenterol. 98 (2003) 332-339
-
(2003)
Am. J. Gastroenterol.
, vol.98
, pp. 332-339
-
-
Van Assche, G.1
Vanbeckevoort, D.2
Bielen, D.3
Coremans, G.4
Aerden, I.5
Noman, M.6
D'Hoore, A.7
Penninckx, F.8
Marchal, G.9
Cornillie, F.10
Rutgeerts, P.11
-
91
-
-
44649090092
-
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial
-
Van Assche G., Magdelaine-Beuzelin C., D'Haens G., Baert F., Noman M., Vermeire S., Ternant D., Watieer H., Paintaud G., and Rutgeerts P. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 134 (2008) 1861-1868
-
(2008)
Gastroenterology
, vol.134
, pp. 1861-1868
-
-
Van Assche, G.1
Magdelaine-Beuzelin, C.2
D'Haens, G.3
Baert, F.4
Noman, M.5
Vermeire, S.6
Ternant, D.7
Watieer, H.8
Paintaud, G.9
Rutgeerts, P.10
-
92
-
-
0036188187
-
Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy
-
Van Den Bosch F., Kruithof E., Baeten D., Herssens A., de Keyser F., Mielants H., and Veys E.M. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy. Arthritis and Rheumatism 46 (2002) 755-765
-
(2002)
Arthritis and Rheumatism
, vol.46
, pp. 755-765
-
-
Van Den Bosch, F.1
Kruithof, E.2
Baeten, D.3
Herssens, A.4
de Keyser, F.5
Mielants, H.6
Veys, E.M.7
-
93
-
-
13444253765
-
Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized placebo-controlled trial (ASSERT)
-
the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group
-
Van der Heijde D., Dijkmans B., Geusens P., Sieper J., De Woody K., Williamson P., Braun J., and the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized placebo-controlled trial (ASSERT). Arthritis Rheum. 52 (2005) 582-591
-
(2005)
Arthritis Rheum.
, vol.52
, pp. 582-591
-
-
Van der Heijde, D.1
Dijkmans, B.2
Geusens, P.3
Sieper, J.4
De Woody, K.5
Williamson, P.6
Braun, J.7
-
94
-
-
33749434256
-
Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn
-
Vasiliauskas E.A., Church J.A., Silverman N., Barry M., Targan S.R., and Dubinsky M.C. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin. Gastroenterol. Hepatol. 4 (2006) 1255-1258
-
(2006)
Clin. Gastroenterol. Hepatol.
, vol.4
, pp. 1255-1258
-
-
Vasiliauskas, E.A.1
Church, J.A.2
Silverman, N.3
Barry, M.4
Targan, S.R.5
Dubinsky, M.C.6
-
95
-
-
0036732707
-
Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease
-
for the Belgian Group of Infliximab Expanded Access Program in Crohn's Disease
-
Vermeire S., Louis E., Carbonez A., Van Assche G., Noman M., Belaiche J., De Vos M., Van Gossum A., Pescatore P., Fiasse R., Pelckmans P., Reynaert H., D'Haens G., Rutgeerts P., and for the Belgian Group of Infliximab Expanded Access Program in Crohn's Disease. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am. J. Gastroenterol. 97 (2002) 2357-2363
-
(2002)
Am. J. Gastroenterol.
, vol.97
, pp. 2357-2363
-
-
Vermeire, S.1
Louis, E.2
Carbonez, A.3
Van Assche, G.4
Noman, M.5
Belaiche, J.6
De Vos, M.7
Van Gossum, A.8
Pescatore, P.9
Fiasse, R.10
Pelckmans, P.11
Reynaert, H.12
D'Haens, G.13
Rutgeerts, P.14
-
96
-
-
0038109994
-
Autoimmunity associated with anti tumor necrosis factor alpha therapy in Crohn's disease
-
Vermeire S., Noman M., Van Assche G., Baert F., Van Steen K., Esters N., Joossens S., Bossuyt X., and Rutgeerts P. Autoimmunity associated with anti tumor necrosis factor alpha therapy in Crohn's disease. A prospective cohort study. Gastroenterology 125 (2003) 32-39
-
(2003)
A prospective cohort study. Gastroenterology
, vol.125
, pp. 32-39
-
-
Vermeire, S.1
Noman, M.2
Van Assche, G.3
Baert, F.4
Van Steen, K.5
Esters, N.6
Joossens, S.7
Bossuyt, X.8
Rutgeerts, P.9
-
97
-
-
34548130215
-
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease
-
Vermeire S., Noman M., Van Assche G., Baert F., D'Haens G., and Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 56 (2007) 1226-1231
-
(2007)
Gut
, vol.56
, pp. 1226-1231
-
-
Vermeire, S.1
Noman, M.2
Van Assche, G.3
Baert, F.4
D'Haens, G.5
Rutgeerts, P.6
-
98
-
-
34247588035
-
Linear growth improves during infliximab therapy in children with chronically active severe Crohn ́s disease
-
Walters D.T., Gilman A.R., and Griffiths A.M. Linear growth improves during infliximab therapy in children with chronically active severe Crohn ́s disease. Inflamm. Bowel Dis. 13 (2007) 424-430
-
(2007)
Inflamm. Bowel Dis.
, vol.13
, pp. 424-430
-
-
Walters, D.T.1
Gilman, A.R.2
Griffiths, A.M.3
-
99
-
-
33645129604
-
Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis
-
Zochling J., Van der Heijde D., Dougados M., and Braun J. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann. Rheum. Dis. 65 (2006) 423-432
-
(2006)
Ann. Rheum. Dis.
, vol.65
, pp. 423-432
-
-
Zochling, J.1
Van der Heijde, D.2
Dougados, M.3
Braun, J.4
|